Effect of Damaging Rare Mutations in Synapse-Related Gene Sets on Response to Short-term Antipsychotic Medication in Chinese Patients With Schizophrenia

Abstract

; for the Chinese Antipsychotics Pharmacogenomics Consortium IMPORTANCE The underlying mechanism for individual differences in patient response to antipsychotic medication remains unknown. OBJECTIVE To discover genes and gene sets harboring rare variants associated with short-term antipsychotic medication efficacy. DESIGN, SETTING, AND PARTICIPANTS In this multicenter, open-label, randomized clinical trial conducted between July 6, 2010, and December 31, 2011, 3023 patients recruited in China of Chinese Han descent with schizophrenia with total Positive and Negative Syndrome Scale (PANSS) score Ն 60 received a 6-week treatment of antipsychotic medications randomly chosen from 5 atypical and 2 typical antipsychotic medications. Whole-exome sequencing (WES) was performed in 316 participants (grouped into those with the best response [n=156] and those who had no response [n=160] to the antipsychotic medication prescribed), according to the total PANSS score reduction rate after 6 weeks of treatment. Validation was performed using targeted sequencing in an independent sample of 1920 patients. Data analyses was performed between March 15, 2016, and March 1, 2017. MAIN OUTCOMES AND MEASURES Drug efficacy at week 6 was assessed according to the change in PANSS scores from baseline. Extremely good and extremely poor responders were selected for an initial WES association study, from which a subset of genes showing putative association was selected for independent replication with a targeted sequencing approach. RESULTS Of the 3023 patients (1549 [51.24%] female and 1474 [48.8%] male; mean [SD] age, 31.2 [7.9] years), 2336 (77.3%) were eligible for genetic analysis. After quality-control exclusions, 316 patients (10.5%) were included for WES and 1920 (63.5%) were included for replication. In the WES discovery stage, 2 gene sets (reduced NMDA [N-methyl-D-aspartate]mediated synaptic currents and reduced AMPA [α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid]-mediated synaptic currents) were found to be enriched with rare damaging variants in the nonresponder group, suggesting the involvement of these gene sets in antipsychotic medication efficacy. Reduced NMDA-mediated synaptic currents gene set was further replicated in an independent sample using targeting sequencing. No statistically significant differences in antipsychotic drug response were found among the patients who received different antipsychotic drugs. CONCLUSIONS AND RELEVANCE Genetic variation in glutamatergic or NMDA neurotransmission is implicated in short-term antipsychotic medication efficacy; WES may have utility in the study of rare genetic variation in pharmacogenetics.

The influence of common polygenic risk and gene sets on social skills group training response in autism spectrum disorder

“…In addition to PRS, gene-set analysis can be utilized to group multiple genetic variants in genes and further to related gene sets to unravel biological processes and cellular functions related to intervention responses 8 . Relevant gene-set associations have been identified for interventions in psychiatry [8][9][10][11][12] . For example, genetic variations in genes underlying glutamatergic or NMDA neurotransmission have been implicated in short-term antipsychotic medication efficacy in schizophrenia, and the calcium signaling pathway has been indicated to respond to selective serotonin reuptake inhibitors in obsessive-compulsive disorder 10,12 .…”

“…Relevant gene-set associations have been identified for interventions in psychiatry 8 – 12 . For example, genetic variations in genes underlying glutamatergic or NMDA neurotransmission have been implicated in short-term antipsychotic medication efficacy in schizophrenia, and the calcium signaling pathway has been indicated to respond to selective serotonin reuptake inhibitors in obsessive-compulsive disorder 10 , 12 .…”

Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial

“…Some studies have already been published using these data. 22,23 Consensus diagnoses were made by at least two experienced psychiatrists based on unstructured interviews with the patients and patients' families, as well as the review of patients' medical records. According to the study protocol, participants were randomly assigned (1:1:1:1:1:½:½) to five atypical antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole and ziprasidone) and two typical antipsychotics (perphenazine and haloperidol) using a random allocation sequence generated by a computer.…”

Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia

“…Pharmacotherapy of conditions such as diabetes and cardiovascular diseases are important interventions in reducing the health disparities between persons with schizophrenia and the general population. 5 , 14 , 32 Although life expectancy in persons with schizophrenia in Finland has been improving at a similar rate as among those without the disease, the disparity between these populations has remained the same. 4 Increasing adherence to cardiometabolic drugs thus remains an important goal for health policymakers, as well.…”